Human Growth Hormone

Human Growth Hormone

• Home
• What is HGH?
• Search
• Syndicate
• More Health

See Also

Human Growth Hormone > Somatropin > California

Please select a HGH news story from the list below:

• Business Wire - Generic Biotech Medicines Could Save Plan Sponsors and Patients $71 Billion
• Business Wire - Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva
• Biotech Equipment Update - FDA APPROVES NUTROPIN AQ PEN FOR DELIVERY OF GROWTH HORMONE.(Genetech Inc.)
• Business Wire - FDA Approves Nutropin AQ Pen for Delivery of Nutropin AQ Recombinant Growth Hormone
• Business Wire - Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech; Schwarz Pharma to Focus on Central Nervous System and Urology
• Business Wire - Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000
• Business Wire - Genentech and Alkermes to Expand Clinical Development of Nutropin Depot
• Biotech Financial Reports - GENENTECH REPORTS 21% INCREASE IN 1ST QTR PRODUCT SALES.(Brief Article)(Statistical Data Included)
• Business Wire - Genentech Reports 21 Percent Increase in Product Sales for First Quarter; 27 Percent Increase in Earnings Per Share, Exclusive of Impact of Redemption
• Business Wire - GENENTECH REPORTS 1999 YEAR-END RESULTS; 1999 Revenues Driven by 45 Percent Increase in Product Sales

Business Wire - Generic Biotech Medicines Could Save Plan Sponsors and Patients $71 Billion

February 15, 2007 -- ST. LOUIS -- Generic biotech medicines could save U.S. plan sponsors and patients $71 billion over ten years, with $3.5 billion of the savings...

• Business Wire - Generic Biotech Medicines Could Save Plan Sponsors and Patients $71 Billion

Business Wire - Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva

August 8, 2002 -- Business Editors/Health & Medical Writers GENEVA & SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Aug. 7, 2002 Serono S.A. (virt-x:...

• Business Wire - Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva

Biotech Equipment Update - FDA APPROVES NUTROPIN AQ PEN FOR DELIVERY OF GROWTH HORMONE.(Genetech Inc.)

June 1, 2002 -- Genentech, Inc. (NYSE:DNA), South San Francisco, has announced that the Nutropin AQ Pen(TM) has received clearance from the FDA. The Nutropin AQ...

• Biotech Equipment Update - FDA APPROVES NUTROPIN AQ PEN FOR DELIVERY OF GROWTH HORMONE.(Genetech Inc.)

Business Wire - FDA Approves Nutropin AQ Pen for Delivery of Nutropin AQ Recombinant Growth Hormone

April 23, 2002 -- Business Editors/Health & Medical Writers SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 23, 2002 Latest Innovation from Genentech's...

• Business Wire - FDA Approves Nutropin AQ Pen for Delivery of Nutropin AQ Recombinant Growth Hormone

Business Wire - Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech; Schwarz Pharma to Focus on Central Nervous System and Urology

June 8, 2001 -- Business Editors SOUTH SAN FRANCISCO, Calif. & MONHEIM, Germany--(BUSINESS WIRE)-- June 7, 2001 Schwarz Pharma AG and Genentech, Inc. announced...

• Business Wire - Schwarz Pharma's Rights to Growth Hormone Products Reacquired by Genentech; Schwarz Pharma to Focus on Central Nervous System and Urology

Business Wire - Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000

January 18, 2001 -- Business Editors/Medical & Health Writers SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 18, 2001 2000 Performance Driven by 23 Percent...

• Business Wire - Genentech Reports 30 Percent Increase in Net Income and 28 Percent Increase in Earnings Per Share for 2000

Business Wire - Genentech and Alkermes to Expand Clinical Development of Nutropin Depot

January 8, 2001 -- Business Editors/Medical Writers SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BW HealthWire)-- Jan. 8, 2001 Genentech, Inc. (NYSE:DNA) and...

• Business Wire - Genentech and Alkermes to Expand Clinical Development of Nutropin Depot

Biotech Financial Reports - GENENTECH REPORTS 21% INCREASE IN 1ST QTR PRODUCT SALES.(Brief Article)(Statistical Data Included)

May 1, 2000 -- Genentech, Inc. (NYSE:DNA), South San Francisco, has announced a 21 percent increase in product sales and a 27 percent increase in earnings per...

• Biotech Financial Reports - GENENTECH REPORTS 21% INCREASE IN 1ST QTR PRODUCT SALES.(Brief Article)(Statistical Data Included)

Business Wire - Genentech Reports 21 Percent Increase in Product Sales for First Quarter; 27 Percent Increase in Earnings Per Share, Exclusive of Impact of Redemption

April 12, 2000 -- Business Editors and Health/Medical Writers SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--April 12, 2000 Genentech, Inc. (NYSE:DNA) today...

• Business Wire - Genentech Reports 21 Percent Increase in Product Sales for First Quarter; 27 Percent Increase in Earnings Per Share, Exclusive of Impact of Redemption

Business Wire - GENENTECH REPORTS 1999 YEAR-END RESULTS; 1999 Revenues Driven by 45 Percent Increase in Product Sales

January 20, 2000 -- Business Editors &Biotech Writers SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 20, 2000 Genentech, Inc. (NYSE: DNA) announced today the...

• Business Wire - GENENTECH REPORTS 1999 YEAR-END RESULTS; 1999 Revenues Driven by 45 Percent Increase in Product Sales

Cities

cambridge medical writers south san francisco monheim south san francisco st. louis

Province/States

california massachusetts

Countries

germany united states

Company

2001 schwarz pharma ag

Product

nutropin aq pen